CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 310 filers reported holding CRISPR THERAPEUTICS AG in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,951,634 | -27.3% | 351,435 | -10.1% | 0.00% | 0.0% |
| Q2 2023 | $21,941,756 | +3.1% | 390,840 | -16.9% | 0.00% | 0.0% |
| Q1 2023 | $21,281,892 | +3.1% | 470,526 | -7.3% | 0.00% | 0.0% |
| Q4 2022 | $20,641,785 | -46.1% | 507,793 | -13.3% | 0.00% | -60.0% |
| Q3 2022 | $38,285,000 | +11.0% | 585,844 | +3.2% | 0.01% | +25.0% |
| Q2 2022 | $34,485,000 | +6.2% | 567,458 | +9.7% | 0.00% | 0.0% |
| Q1 2022 | $32,476,000 | -21.2% | 517,388 | -4.8% | 0.00% | -20.0% |
| Q4 2021 | $41,189,000 | -36.6% | 543,510 | -6.3% | 0.01% | -44.4% |
| Q3 2021 | $64,921,000 | -22.8% | 580,021 | +11.6% | 0.01% | -18.2% |
| Q2 2021 | $84,145,000 | -20.4% | 519,765 | -40.1% | 0.01% | -31.2% |
| Q1 2021 | $105,678,000 | -5.6% | 867,268 | +18.6% | 0.02% | -5.9% |
| Q4 2020 | $111,988,000 | +165.9% | 731,427 | +45.3% | 0.02% | +112.5% |
| Q3 2020 | $42,114,000 | +2.1% | 503,500 | -10.3% | 0.01% | -11.1% |
| Q2 2020 | $41,251,000 | +14.2% | 561,313 | -34.1% | 0.01% | -10.0% |
| Q1 2020 | $36,113,000 | +132.3% | 851,519 | +233.6% | 0.01% | +150.0% |
| Q4 2019 | $15,547,000 | +46.6% | 255,264 | -1.3% | 0.00% | +33.3% |
| Q3 2019 | $10,605,000 | -21.0% | 258,741 | -9.2% | 0.00% | -25.0% |
| Q2 2019 | $13,423,000 | +39.9% | 284,984 | +6.1% | 0.00% | +33.3% |
| Q1 2019 | $9,595,000 | +73.9% | 268,623 | +39.0% | 0.00% | +50.0% |
| Q4 2018 | $5,519,000 | -46.5% | 193,186 | -16.9% | 0.00% | -33.3% |
| Q3 2018 | $10,313,000 | -10.7% | 232,540 | +18.4% | 0.00% | 0.0% |
| Q2 2018 | $11,544,000 | +161.4% | 196,442 | +103.3% | 0.00% | +200.0% |
| Q1 2018 | $4,417,000 | +111.8% | 96,620 | +8.8% | 0.00% | 0.0% |
| Q4 2017 | $2,085,000 | +200.9% | 88,806 | +129.1% | 0.00% | – |
| Q3 2017 | $693,000 | -94.2% | 38,770 | -94.8% | 0.00% | -100.0% |
| Q2 2017 | $11,979,000 | +1239.9% | 747,722 | +1721.4% | 0.00% | – |
| Q1 2017 | $894,000 | +480.5% | 41,052 | +437.9% | 0.00% | – |
| Q4 2016 | $154,000 | – | 7,632 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |